Patents Examined by Erich A. Leeser
  • Patent number: 11357779
    Abstract: A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: June 14, 2022
    Assignee: G1 Therapeutics, Inc.
    Inventors: Andrew Beelen, Jay Copeland Strum
  • Patent number: 11358950
    Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 14, 2022
    Assignee: CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Guoping Hu, Jian Li, Shuhui Chen
  • Patent number: 11352345
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: June 7, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Hao Zhang, Jun Li, Tianan Fang, James R. Corte
  • Patent number: 11344554
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: May 31, 2022
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • Patent number: 11344543
    Abstract: The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 31, 2022
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
  • Patent number: 11344536
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: May 31, 2022
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 11339148
    Abstract: The invention relates to crystalline forms of (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide; processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CXCR7 receptor modulators.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: May 24, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD.
    Inventors: Philippe Guerry, Markus Von Raumer
  • Patent number: 11325912
    Abstract: A method of regio-selectively synthesizing an imidazo-pyrimidine compound of formulae (XXa) or (XXb) comprising a step of coupling a first compound of formula XX-P1a or XX-P1b with a second compound of formula XX-P2 This annulation reaction between ?-ethoxy acrylamides and phosphorylated aminoimidazoles to furnish imidazo[1,2-a]pyrimidin-amines relies on steering effects from endocyclic and exocyclic phosphorylated aminoimidazoles. The reaction furnishes either 2-amino or 4-amino constitutional isomers of imidazo[1,2-a]pyrimidines with good yields and ranges of 90:10-99:1 regio-selectivity. The reaction is useful in the synthesis of various tracer molecules used in the study of neurological conditions such as where R3 and R4 together with the imidazole ring atoms to which they are bonded form a phenyl ring and the products are substituted benzimidazopyrimidines.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: May 10, 2022
    Assignee: Genentech, Inc.
    Inventors: Kyle Bradley Pascual Clagg, Nicholas Andrew White, Haiming Zhang, Francis Gosselin, William Nack, Paul D. O'Shea
  • Patent number: 11325910
    Abstract: The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: May 10, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Nicholas Paul Kwiatkowski
  • Patent number: 11325919
    Abstract: Aleutianamine represents the first in a new class of pyrroloiminoquinone alkaloids possessing a highly strained multi-bridged ring system, discovered from Latrunculia (Latrunculia) austini Samaai, Kelly & Gibbons, 2006 (class Demospongiae, order Poecilosclerida, family Latrunculiidae) recovered during a NOAA deep-water exploration of the Aleutian Islands. Aleutianamine exhibited potent and selective cytotoxicity toward solid tumor cell lines including pancreatic cancer (PANC-1) with an IC50 of 25 nM and colon cancer (H116) with IC50 of 1 ?M.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: May 10, 2022
    Inventor: Mark T. Hamann
  • Patent number: 11325901
    Abstract: Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 10, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Kai Ding, Ziyuan Zhou
  • Patent number: 11319327
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: May 3, 2022
    Assignees: Temple University—Of The Commonwealth System of Higher Education, Praeventix, LLC
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • Patent number: 11319329
    Abstract: The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 3, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Nidhi Arora, Genesis M. Bacani, Joseph Kent Barbay, Scott D. Bembenek, Charlotte Pooley Deckhut, James P. Edwards, Brahmananda Ghosh, Kevin D. Kreutter, Mark S. Tichenor, Jennifer D. Venable, Jianmei Wei, John J. M. Wiener
  • Patent number: 11322692
    Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having low driving voltage, high luminous efficiency, and/or improved lifespan characteristics can be provided.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 3, 2022
    Inventor: Doo-Hyeon Moon
  • Patent number: 11312702
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: April 26, 2022
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Yimin Qian, Wei He, Ke Liu
  • Patent number: 11306094
    Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: April 19, 2022
    Assignee: MERCK & CIE
    Inventors: Rudolf Moser, Viola Groehn, Thomas Egger, Thomas Ammann
  • Patent number: 11306068
    Abstract: The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: April 19, 2022
    Assignee: Inthera Bioscience AG
    Inventors: Marc Labelle, Ulrich Kessler, Valentino Cattori, Cyril Cook, Ramkrishna Reddy Vakiti, Kevin R. D. Johnson, Matinder Kaur, Jean-d'amour K. Twibanire, Farman Ullah
  • Patent number: 11292774
    Abstract: Provided is a method for the synthesis of N-protected 3,6-bis-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: April 5, 2022
    Assignee: MannKind Corporation
    Inventors: John J. Stevenson, Destardi Moye-Sherman
  • Patent number: 11285159
    Abstract: The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: March 29, 2022
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: John Hayslip, Leanne M. Holes, Sven Mensing, Silpa Nuthalapati
  • Patent number: 11279679
    Abstract: The present application relates to methods of preparing Compound A: or a salt thereof, and a polymorph of Compound A dihydrochloride salt:
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: March 22, 2022
    Assignee: ArQule, Inc.
    Inventors: Craig Bates, Jianmin Mao, David P. Reed